

## Coley Pharmaceutical Group

[View the current Coley Pharmaceutical Group Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/21156-Coley+Pharmaceutical+Group.html)

(<http://www.bioportfolio.com/bi corporate/21156-Coley+Pharmaceutical+Group.html>)

### Contact Details:

**93 Worcester Street, Suite 101**

**Wellesley**

**Massachusetts**

**02481**

**United States of America**

Tel: 1 781 431 9000

Fax: 1 781 431 6403

Email: [corpcomm@coleypharma.com](mailto:corpcomm@coleypharma.com)

Our proprietary TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease. Coley's pipeline of TLR Therapeutics includes four clinical-stage products targeting cancer, viral diseases, asthma and allergy:

### Recent Publications by Coley Pharmaceutical Group:



- [Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.](#)  
*The anti-tumor properties of Toll-like receptor (TLR) 9 agonist CpG...* 4th March, 2009  
Coley Pharmaceutical Group-A Pfizer Company, 340 Terry Fox Drive, suite- Cancer Immunol Immunother. 2009 Apr;58(4):615-28. Epub 2008 Sep 19. ([DOI Direct Link](#))
- [Novel Vaccines and Adjuvant Systems: The Utility of Animal Models for Predicting Immunogenicity in Humans.](#)  
*Animal models are essential for acquiring safety, immunogenicity and...* 3rd April, 2008  
Coley Pharmaceutical Group, 340 Terry Fox Drive, Suite 200, Ottawa ON,- Hum Vaccin. 2007 Nov 18;4(3).
- [Immunology. The toll of cathepsin K deficiency.](#)  
*Animal models are essential for acquiring safety, immunogenicity and...* 13th February, 2008  
Coley Pharmaceutical Group, 93 Worcester Street, Wellesley, MA 02481, USA.- Science. 2008 Feb 1;319(5863):576-7. ([DOI Direct Link](#))
- [Toll-like receptor 9 \(TLR9\) agonists in the treatment of cancer.](#)  
*Although still early in clinical development, agonists of Toll-like...* 6th February, 2008  
Coley Pharmaceutical Group Inc., Wellesley, MA 02481, USA.- Oncogene. 2008 Jan 7;27(2):161-7. (

[DOI Direct Link](#))

- [Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.](#)  
*Toll-like receptors (TLRs) detect infections by highly conserved...*18th January, 2008  
Coley Pharmaceutical Group Inc., Wellesley, MA, USA.- Immunol Rev. 2007 Dec;220:251-69. ([DOI Direct Link](#))
- [The toll of too much TLR7.](#)  
*Toll-like receptor 7 (TLR7) detects viral RNA, but can be activated...*17th January, 2008  
Coley Pharmaceutical Group, 93 Worcester Street, Suite 101, Wellesley, MA- Immunity. 2007 Nov;27(5):695-7. ([DOI Direct Link](#))
- [Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 \(ACTILON\), an investigational synthetic toll-like receptor 9 agonist.](#)  
*CPG 10101 (ACTILON) is a novel potent and selective unmethylated...*20th October, 2007  
Coley Pharmaceutical- Antivir Ther. 2007;12(5):741-51.
- [Antiinfective applications of toll-like receptor 9 agonists.](#)  
*The innate immune system detects pathogens by the presence of highly...*19th September, 2007  
Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101,- Proc Am Thorac Soc. 2007 Jul;4(3):289-94. ([DOI Direct Link](#))
- [Development of TLR9 agonists for cancer therapy.](#)  
*In vertebrates, the TLRs are a family of specialized immune receptors that...*15th June, 2007  
Coley Pharmaceutical Group, 93 Worcester Street, Wellesley, MA 02481, USA.- J Clin Invest. 2007 May;117(5):1184-94. ([DOI Direct Link](#))
- [Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.](#)  
*The adaptive immune system-with its remarkable ability to generate...*15th November, 2006  
Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101,- Curr Top Microbiol Immunol. 2006;311:155-78.
- [Therapeutic potential of Toll-like receptor 9 activation.](#)  
*In the decade since the discovery that mouse B cells respond to certain...*19th July, 2006  
Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101,- Nat Rev Drug Discov. 2006 Jun;5(6):471-84. ([DOI Direct Link](#))
- [Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod \(R-848\).](#)  
*The mammalian innate immune system recognizes pathogens via a series of...*7th June, 2006  
Coley Pharmaceutical Group, 340 Terry Fox Drive, Suite 200, Ottawa, Ont.,- Antiviral Res. 2006 Feb;69(2):77-85. Epub 2005 Dec 5. ([DOI Direct Link](#))
- [TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod \(R-848\).](#)  
*TLR ligands that mimic pathogen associated molecular patterns and activate...*13th December, 2005  
Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2.- Vaccine. 2005 Nov 1;23(45):5263-70. Epub 2005 Jul 18. ([DOI Direct Link](#))
- [Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.](#)  
*Subcutaneous injection of normal human volunteers with a B-class CpG...*19th April, 2005  
Coley Pharmaceutical Group, Wellesley, Massachusetts 02481, USA.- J Immunother. 2004 Nov-Dec;27(6):460-71.
- [Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid \(LNA\).](#)  
*Locked nucleic acid (LNA) is an RNA derivative that when introduced into...*17th November, 2004  
Coley Pharmaceutical Group, D-40764 Langenfeld, Germany.- Oligonucleotides. 2004 Spring;14(1):23-31. ([DOI Direct Link](#))

**Press Releases on Coley Pharmaceutical Group:**

<a href="#">Marianjoy Medical Group Physician Receives James Brady Award</a>	24th November, 2009	Marianjoy Rehabilitation Hospital	WHEATON, Ill., Nov. 24 /PRNewswire-USNewswire/ -- Dr. Nelson Escobar, a physician with the Marianjoy Medical Group, has been named the recipient of the James Brady Award. The award was presented to
<a href="#">NIP Acquires San Diego Executive Benefits Firm</a>	24th November, 2009	NIP, Inc.	AUSTIN, Texas, Nov. 24 /PRNewswire/ -- NIP, Inc. today announced the acquisition of Retirement Capital Group ["RCG"], one of the nation's leading executive compensation and benefit plan
<a href="#">Guardian to Continue Following Its Current Coverage Guidelines for Mammography Screenings</a>	24th November, 2009	The Guardian Life Insurance Company of America	NEW YORK, Nov. 24 /PRNewswire/ -- The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized
<a href="#">IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009</a>	24th November, 2009	IPC The Hospitalist Company, Inc.	NORTH HOLLYWOOD, Calif., Nov. 24 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national hospitalist physician group practice company, announced today that
<a href="#">Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA</a>	24th November, 2009	Lotus Pharmaceuticals, Inc.	BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of

## BioNews Results for Coley Pharmaceutical Group



- [Nucleic acid compositions for stimulating immune responses](#)  
PharmCast: Nov 6 2009 5:24AM Matching: coley pharmaceutical group
- [Immunostimulatory nucleic acids for the treatment of asthma and allergy](#)  
PharmCast: Sep 23 2009 12:36PM Matching: coley pharmaceutical group

## Coley Pharmaceutical Group Clinical Trials:



- [Phase I Study of Safety and Immunogenicity of AMA1-C1Ahydrogel + CPG 7909 Vaccine for Malaria](#)

## Coley Pharmaceutical Group Patents:



- 7605138- [Nucleic acid compositions for stimulating immune responses](#)
- 6207646- [Immunostimulatory nucleic acid molecules](#)
- 6239116- [Immunostimulatory nucleic acid molecules](#)
- 6727230- [Immune stimulation by phosphorothioate oligonucleotide analogs](#)
- 6949520- [Methods related to immunostimulatory nucleic acid-induced interferon](#)
- 7276515- [Thioether substituted imidazoquinolines](#)
- 7393859- [Amide substituted imidazoquinolines](#)
- 7410975- [Small molecule toll-like receptor \(TLR\) antagonists](#)
- 7544697- [Pyrazolopyridines and analogs thereof](#)
- 7566703- [Semi-soft C-class immunostimulatory oligonucleotides](#)
- 7569553- [Nucleic acid compositions for stimulating immune responses](#)
- 7576066- [Nucleic acid compositions for stimulating immune responses](#)
- 7585847- [Immunostimulatory nucleic acids for the treatment of asthma and allergy](#)
- 7598382- [Aryl substituted imidazoquinolines](#)
- 6194388- [Immunomodulatory oligonucleotides](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast

service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

